Eli Frydman

We imagine a world where the most advanced technologies in the field of artificial intelligence are harnessed to make healthcare better, affordable, and more widely available. Our amazing human-machine hybrid AI diagnostic system allows us to build powerful predictive analytics models that solve a worldwide challenge – strained health budgets and workforces.

Carevature Medical was founded with a primary goal to improve the tools available to spine surgeons for spinal decompression. Decompression of the neural elements and/or spinal canal is the most critical aspect of surgical intervention for degenerative spinal conditions, and yet for decades there has been little to no innovation in improving the tools for spinal decompression (Kerrisons, osteotomes, etc.). Numerous advancements in implant technology, navigation, and robotics have been introduced in recent years, however surgeons are still largely using the same tools for spinal decompression that have been used since the 1980s. Carevature is changing this with Dreal® technology, a platform of sterile packed, single use, curved at the tip, high-speed bone removal devices that are shielded to protect nearby neural structures. Dreal® technology allows spine surgeons to decompress the neural elements while retaining structural bone, preserving spinal stability and in some cases, offering the potential to avoid spinal fusion. The devices are optimized for MIS tubular approaches, with versions for mini-open and open techniques as well. Dreal® technology can be used in numerous applications, including ACDF, Cervical Corpectomy, Facet-preserving Lumbar foraminotomy, endplate prep for TLIF, MIS removal of thoracic hard disc pathology, and many others. Potential benefits of the Dreal® platform include safer, faster, and more efficient spinal procedures, as well as the possibility to avoid fusion in select cases, and the resulting opportunity for shorter hospital stays and a quicker return to work and/or the activities of daily living.

Nanox AI is lighting up new pathways for smart population healthcare management with AI-based solutions, identifying patients at risk of having chronic disease and enabling the start of preventative care pathways. Integrated delivery networks and payers benefit from this technology with more accurate risk-adjustment, timely intervention, and improved quality of health services, while significantly reducing the associated costs. Nanox AI enables better, fairly reimbursed population health management and wellbeing for larger patient populations. #population health #AI #machine learning #digitalhealth #medicalimaging

Beyeonics is all about empowering surgeons with OR surgical digital consolidating platforms using enhanced imaging, advanced data processing, AI, and surgical navigation technologies that are all naturally displayed and controlled through an immersive Augmented Reality Surgical Headset. We introduce innovation to healthcare with surgeon-centric surgical platforms originally developed by a leading global aviation company for pilots. Technologies that now serve us to address the present and future surgical needs in Ophthalmology, Orthopedics, and Neurosurgery. We believe in and practice innovation, commitment, and performance to drive our technologies to fulfillment and invest in our Beyeonics human power teams to meet our long-term cause. Beyeonics represents a group of medical technology companies executing our mission. Beyeonics Vision Ltd and Beyeonics Surgical Ltd are medical technology companies dedicated to developing and commercially introducing our surgeon’s empowering platform technologies to various clinical specialties.

Scopio Labs is transforming cell morphology analysis, offering fully digital applications, platforms, and diagnostic support that enhance clinical workflows. By assisting lab experts with fast, early, and accurate detection and diagnosis of disease, Scopio expedites patients access to life-saving treatments. .

Precise Bio develops and commercializes 4D bio-fabricated functional tissues and organs that can save lives and improve its quality. We combine world-class tissue-engineering and transplantation experience with best-in-class bio-printing, to create a scalable bio-fabrication platform, that can overcome current industry challenges and make complex human organs available for transplantation.

We are a global clinical-stage bio-pharmaceutical company focused on developing, manufacturing and commercializing novel, locally administered therapies to improve surgical outcomes. Our PLEX (Polymer-Lipid Encapsulation matriX) technology is a unique platform that is anchored in the surgical site to provide controlled and continuous delivery of medications. Our product candidates are designed to deliver medications in the body over days to several months in a controlled manner. This allows surgeons to deliver medication right to the surgical site to improve patient outcomes in localized medical conditions such as; infection, pain, inflammation and cancer. Our initial infection treatment targets are Surgical Site Infections (SSIs), the second most prevalent type of Healthcare Acquired Infections (HAIs). SSIs have substantial negative impact on patients’ clinical outcomes and also pose a significant healthcare system burden. We strive to reduce overall surgical infection rates, including infections due to antibiotic-resistant bacteria which the FDA defined as being one of the world’s most pressing public health problems. NASDAQ: PYPD

Nucleix is a liquid biopsy company revolutionizing cancer treatment with earlier disease detection at a time when intervention can bring the greatest impact for patients. Leveraging NGS-based and PCR-based technology to identify methylation changes, the Company’s pioneering testing approach uses methylation-based identification for early-stage and recurring cancer detection. The Company’s non-invasive EpiCheck® delivers highly accurate and sensitive results, all while providing a seamless testing option for physicians, patients, and the healthcare system. The Company is building an EpiCheck® franchise, beginning with the Bladder EpiCheck® kit, CE-marked and available in Europe for primary and recurrent bladder cancer and upper tract urinary cancer, and FDA 510(k) cleared for bladder cancer recurrence in the United States. The Company is advancing its Lung EpiCheck® test towards commercialization for high-risk individuals while evaluating additional tests for other high-risk diseases.

We imagine a world where the most advanced technologies in the field of artificial intelligence are harnessed to make healthcare better, affordable, and more widely available. Our amazing human-machine hybrid AI diagnostic system allows us to build powerful predictive analytics models that solve a worldwide challenge – strained health budgets and workforces.

Carevature Medical was founded with a primary goal to improve the tools available to spine surgeons for spinal decompression. Decompression of the neural elements and/or spinal canal is the most critical aspect of surgical intervention for degenerative spinal conditions, and yet for decades there has been little to no innovation in improving the tools for spinal decompression (Kerrisons, osteotomes, etc.). Numerous advancements in implant technology, navigation, and robotics have been introduced in recent years, however surgeons are still largely using the same tools for spinal decompression that have been used since the 1980s. Carevature is changing this with Dreal® technology, a platform of sterile packed, single use, curved at the tip, high-speed bone removal devices that are shielded to protect nearby neural structures. Dreal® technology allows spine surgeons to decompress the neural elements while retaining structural bone, preserving spinal stability and in some cases, offering the potential to avoid spinal fusion. The devices are optimized for MIS tubular approaches, with versions for mini-open and open techniques as well. Dreal® technology can be used in numerous applications, including ACDF, Cervical Corpectomy, Facet-preserving Lumbar foraminotomy, endplate prep for TLIF, MIS removal of thoracic hard disc pathology, and many others. Potential benefits of the Dreal® platform include safer, faster, and more efficient spinal procedures, as well as the possibility to avoid fusion in select cases, and the resulting opportunity for shorter hospital stays and a quicker return to work and/or the activities of daily living.

Nanox AI is lighting up new pathways for smart population healthcare management with AI-based solutions, identifying patients at risk of having chronic disease and enabling the start of preventative care pathways. Integrated delivery networks and payers benefit from this technology with more accurate risk-adjustment, timely intervention, and improved quality of health services, while significantly reducing the associated costs. Nanox AI enables better, fairly reimbursed population health management and wellbeing for larger patient populations. #population health #AI #machine learning #digitalhealth #medicalimaging